Per todays PR, the next P trial (not stated if a 2b, 2/3, or 3) will be for moderate to severe psoriasis. I think it is fair to say that the company did not see enough improvment in patients witg mild psoriasis to move forward.
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
